Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Deferred Revenue: 2024-2025

Historic Current Deferred Revenue for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $48.8 million.

  • Kura Oncology's Current Deferred Revenue was N/A to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year change of. This contributed to the annual value of $24.3 million for FY2024, which is N/A change from last year.
  • Per Kura Oncology's latest filing, its Current Deferred Revenue stood at $48.8 million for Q3 2025, which was down 1.39% from $49.4 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Current Deferred Revenue peaked at $49.4 million during Q2 2025, and registered a low of $24.3 million during Q4 2024.